bluebird bio CFO Christopher Krawtschuk departs June 10; O. James Sterling appointed as CFO

bluebird bio, Inc.

CFO Christopher Krawtschuk to depart June 10, 2024, not due to any disagreement with the company on accounting policies or strategy.
O. James Sterling, formerly CFO of Renalytix plc, appointed as CFO and principal accounting officer effective June 10, 2024.
Sterling's compensation: $500k base salary, $100k sign-on bonus, 45% target bonus, and initial equity grant of 300k options, 100k RSUs, and 50k PRSUs (subject to shareholder approval).
Severance upon termination without cause or for good reason includes one times base salary (or one times base plus target bonus within 12 months of Change in Control) plus COBRA subsidy for 12 months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Krawtschuk

Chief Financial Officer

bluebird bio, Inc.

Effective: 2024-06-10
Successor: O. James Sterling
Filed: May 29, 2024, 7:59 PM ET

Effective June 10, 2024 (the “Separation Date”), Christopher Krawtschuk will depart bluebird bio, Inc. (the “Company”) and cease serving as Chief Financial Officer and principal accounting officer.

Appointed

O. James Sterling

Chief Financial Officer

bluebird bio, Inc.

Effective: 2024-06-10
Filed: May 29, 2024, 7:59 PM ET

On May 28, 2024, the Board of Directors (the “Board”) appointed O. James Sterling as Chief Financial Officer of the Company and designated Mr. Sterling as principal accounting officer, effective as of the date Mr. Sterling commences employment with the Company, which is expected to be June 10, 2024 (the “Transition Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Krawtschuk departed as Chief Financial Officer at bluebird bio, Inc..

Action: will depart
Role: Chief Financial Officer

Exact text from the filing

Effective June 10, 2024 (the “Separation Date”), Christopher Krawtschuk will depart bluebird bio, Inc. (the “Company”) and cease serving as Chief Financial Officer and principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

O. James Sterling was appointed as Chief Financial Officer at bluebird bio, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 28, 2024, the Board of Directors (the “Board”) appointed O. James Sterling as Chief Financial Officer of the Company and designated Mr. Sterling as principal accounting officer, effective as of the date Mr. Sterling commences employment with the Company, which is expected to be June 10, 2024 (the “Transition Date”).

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-148602

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.